Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is a paper indexed in PICO Portal from OpenAlex.

How many citations does Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study have?

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has 111 citations in the OpenAlex counts PICO Portal stores.

When was Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study published?

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has 2010 year in the PICO Portal index.

What is the open-access status of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has closed oa status in the PICO Portal index.

What is the DOI of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?

The DOI for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.

What is the PMID of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?

The PMID for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.

What is the OpenAlex record for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?

The OpenAlex for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.